RoboSense Teams Up With Webasto On Smart Roof Module With Integrated MEMS LiDAR
23.4.2021 21:00:00 EEST | Business Wire | Press release
During the Shanghai Auto Show, RoboSense (https://robosense.ai/), a smart and automotive LiDAR system provider, and Webasto (https://www.webasto-group.com/), the global Top 100 automotive supplier and market leader for roof systems, announced cooperation on the Smart Roof Sensor Module that integrated with RoboSense automotive-grade MEMS LiDAR RS-LiDAR-M1 for Level 3 to Level 5 autonomous driving vehicles, largely simplifying the structure and mounting process of conventional sensor sets of self-driving vehicles and ensures advanced safety perception.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210423005484/en/
The M1 is seamlessly embedded into Webasto Roof Sensor Module (Photo: Business Wire)
Through this strategic cooperation, Webasto is committed to seamlessly embedding the RoboSense M1, camera and other sensor systems to the panoramic roof of vehicles to provide safer and more reliable environment perception information at the smallest possible space in the roof. The solution allows different roof systems to be mounted on the vehicle body, creating greater flexibility for the development of autonomous vehicles.
As the world’s market leader, Webasto offers the broadest product range of high-quality roof systems. The rooftop design not only enables the integration of sensor systems but also adopts highly rigid transparent material and the openable top function, which creates the feeling of freedom for the passengers.
The RoboSense M1 boasts 125 ultra-high resolution scanning beams, ultra-wide FOV of 120°*25°, and a maximum detection range of 200m (150M@10%). At present, the M1(thickness 45mm, depth 108mm, width 110mm) is the thinnest solid-state LiDAR on the market. At the highest point of the vehicle, the M1’s unique mounting position in the smart roof module gives it the vantage point of view, which can greatly improve the detection ability of the perception system and ensure the safe and stable operation of the autonomous driving systems. Moreover, it costs less fuel consumption/NEDC mileage than other LiDAR products.
“Webasto looks for the most compact and state-of-the-art perception sensing systems on the market desired by our customers for roof-mounted integration. The RoboSense M1 meets these criteria and provides both promising size and suitability for roof integration”, says Brad Tang, Strategy & Product Planning Manager at Webasto.
Mark Qiu, RoboSense Executive President and Co-Partner says, " By combining the most mature roof module technology and the most compact size MEMS solid-state LiDAR, we provide the elegant, easy-to-integrate and one-stop smart roof solution with safety perception function to OEMs and end-users.”
The SOP version of M1 has fully met the OEM’s all automotive-grade requirements.
- M1 has successfully solved point cloud’s “corner cases” including high reflectivity objects, near-field obstacles, strong ambient light (direct sunlight), and interference from other LiDAR sensors, etc.
- M1 successfully passed the automotive-grade verification tests include mechanical and vibration, shock, EMC electromagnetic compatibility, human eye safety, chemical anti-corrosion, salt spray, high and low-temperature storage and operation, etc.
- Moreover, RoboSense has established China’s first automotive-grade solid-state LiDAR production line and would start mass production and delivery in Q2 2021.
About RoboSense
Founded in 2014, RoboSense (Suteng Innovation Technology Co., Ltd.) is the leading provider of Smart LiDAR Sensor Systems incorporating LiDAR sensors, AI algorithms and IC chipsets, that transform conventional 3D LiDAR sensors to full data analysis and comprehension systems. https://robosense.ai/
About Webasto
The Webasto Group is a global innovative systems partner to almost all automobile manufacturers and among the top 100 suppliers in this industry sector. The company’s product portfolio comprises a broad range of roof and heating systems for every type of vehicle and all drive types as well as battery systems and charging solutions. http://www.webasto-group.com/ or http://www.twitter.com/WebastoGroup
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210423005484/en/
Contact information
Press Contact
Cassie Gong, RoboSense PR
sqgong@robosense.ai
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 13:00:00 EET | Press release
Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022786567/en/ David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck "For people living with TGCT, the impact of the disease is often felt through persis
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release
WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release
Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom